معرفی
Professor Deborah Tweddle is a faculty member at Newcastle University specializing in pediatric oncology, with a primary focus on neuroblastoma and related childhood cancers. Her research spans cancer genetics, clinical pharmacology in neonates and infants, and the application of advanced genomic technologies to improve diagnosis and treatment.
Her research interests center on the genetic underpinnings of neuroblastoma (particularly ALK aberrations), tumor evolution, and evidence-based dosing guidelines for chemotherapy in infants. She employs techniques such as optical genome mapping, cell-free DNA analysis, and serial tumor sequencing to investigate tumor heterogeneity and identify therapeutic targets, with emphasis on translating genomic findings into clinical applications.
Analysis of her 2021-2025 publications reveals consistent focus on neuroblastoma through large collaborative studies including the UK Children's Cancer and Leukaemia Group (UK CCLG) and European Neuroblastoma Study Group (SIOPEN). Her work bridges laboratory research and clinical trials, addressing critical gaps in pediatric pharmacology, tumor genomics, and risk-stratified treatment approaches.
No scientific awards were mentioned in the provided text.
Professor Tweddle leads major research consortia including UK CCLG and SIOPEN trials, indicating significant grant funding and leadership in multinational studies. While specific grant details are absent, her role in nationwide clinical trials (e.g., BEACON-Neuroblastoma) demonstrates substantial research infrastructure. No student mentoring information appears in the current publication records.
She collaborates extensively across UK and European institutions, frequently co-authoring with Newcastle colleagues like Professor Gareth Veal (clinical pharmacology) and Dr. Shelby Barnett, reflecting a team-based approach to advancing neuroblastoma therapeutics through integrated laboratory-clinical frameworks.
